🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Marginal Zone Lymphoma

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma NCT07583810Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma NCT06569680Phase 21 site📍 Miami Izidore Lossos, MD · Tests: Mosunetuzumab Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites📍 Boston📍 New York📍 Columbus Reid Merryman, MD · Tests: Zanubrutinib, Rituximab, Epcoritamab Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma NCT06712459n/a7 sites📍 New York📍 Leuven📍 Paris International Extranodal Lymphoma Study Group (IELSG) Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Cohort Study in Newly Diagnosed MZL NCT06449885n/a1 site📍 Shanghai Fudan University · Tests: patients receive optimal treatment or follow-up according to the characteristics of the disease MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL NCT06793189Phase 23 sites📍 Shanghai📍 Shenyang📍 Beijing Ruijin Hospital · Tests: Obinutuzumab and Orelabrutinib, Obinutuzumab, Orelabrutinib and Lenalidomide, Orelabrutinib, Orelabrutinib Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma NCT07554898Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang Cancer Hospital · Tests: Orelabrutinib, Ultra-low-dose Radiation Therapy Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas NCT06513234Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Orelabrutinib and obinutuzumab Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP) NCT06823960n/a15 sites📍 Alessandria📍 Bologna📍 Catania IRCCS Azienda Ospedaliero-Universitaria di Bologna Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma NCT05700149n/a50 sites📍 Miami📍 Rochester📍 New York International Extranodal Lymphoma Study Group (IELSG) Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Exercise, Diet Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma NCT04491370Phase 1, Phase 21 site📍 Valhalla New York Medical College · Tests: Polatuzumab vedotin Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL NCT07441993Phase 214 sites📍 Guangzhou📍 Zhengzhou📍 Wuhan Institute of Hematology & Blood Diseases Hospital, China · Tests: Orelabrutinib RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma NCT06190301NA1 site📍 Guangzhou Zhongshan Ophthalmic Center, Sun Yat-sen University · Tests: Rituximab, Involved Site Radiation Therapy Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma NCT07355699Phase 43 sites📍 Beijing📍 Beijing📍 Beijing Beijing Tongren Hospital · Tests: Orelabrutinib A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma NCT05929612Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ultra Low Dose 4 Gy Radiation The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy NCT06503276Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Orelabrutinib, Ultra-low dose radiotherapy HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Tafasitamab, Rituximab, Lenalidomide Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286Phase 3171 sites📍 Los Angeles📍 Plantation📍 Indianapolis Regeneron Pharmaceuticals · Tests: Odronextamab, Lenalidomide, Rituximab Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) NCT04110301Phase 1, Phase 21 site📍 Beijing Beijing Mabworks Biotech Co., Ltd. · Tests: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2150 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy